BASF and Bend Research join forces to solve bioavailability challenges
BASF SE and Bend Research Inc. have signed an agreement to jointly evaluate and develop novel excipients to enhance the solubility and bioavailability of poorly soluble drugs.
The companies plan to combine their world-leading expertise in the development of new excipients and drug formulations to provide customers from the pharmaceutical industry with early access to the latest polymer innovations. The aim of this collaboration is to meet increasing challenges of poorly soluble active pharmaceutical ingredients (BCS Class II and IV compounds); the initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble active pharmaceutical ingredients.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Artificial intelligence for better diagnostics - Standardized methods facilitate the evaluation of Raman spectra

New technique shows in detail where drug molecules hit their targets in the body - The new method could speed the development of many new drugs
ChondroGene published paper ´Human genome project and cardiovascular disease genes´ - In landmark textbook ´Molecular Basis of Cardiovascular Disease´
CV Therapeutics Appoints Joseph M. Davie, M.D., Ph.D. to Board of Directors
ProtAffin AG appoints Dr. Simon Moroney to Supervisory Board
PerkinElmer Life Sciences Introduces Protein S-Nitrosylation Detection Technology - New NitroGlo(TM) Detection Kit Offers New Capabilities for Neurobiology Researchers
EPEMED the European Personalised Medicine association appoints its General Delegate and several new board members
